Clinical Trials Directory

Trials / Completed

CompletedNCT04015466

Advanced GC Multi-omic Characterization in EU and CELAC Populations

Status
Completed
Phase
Study type
Observational
Enrollment
800 (actual)
Sponsor
Fundación para la Investigación del Hospital Clínico de Valencia · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers

Summary

Observational study (cohort type) of advanced GC patients that will be recruited prospectively to study biological factors associated with the disease and relevant clinical outcomes.

Detailed description

Despite of multiple attempts to improve treatment in recent decades, none strategies has improved prognosis in locally advanced stage III and IV GC. A therapeutic approach to GC based on current histological and image criteria (Tumour Node Metastasis -TNM- stage) is insufficient. Although multiple targeted agents are currently under investigation, so far, only trastuzumab and ramucirumab have demonstrated efficacy in advanced GC and have a regulatory approval. For this reason, the identification of specific targets that could be susceptible for drug inhibition, is an urgent requirement. Moreover, most studies and current international databases on late-stage/advanced GC are largely based on Asian populations, in sharp contrast tumour biology and genome of EU or CELAC populations remain poorly known. The primary objective of this study are to: 1. Characterize a multi-centric cohort including EU and CELAC populations diagnosed with advanced GC through a multi-omic approach including proteomics, genomics, transcriptomics, microbiome and exposome analysis due to study the determinants of GC. 2. Identify the regional differences in EU and CELAC populations recruiting patients for this study for each omic characterization due to identify the high-risk group populations. 3. Identify and select from the multi-omic approach those biomarkers useful for the development of an algorithm to guide the therapeutic approach for advanced GC.

Conditions

Timeline

Start date
2019-06-12
Primary completion
2023-12-31
Completion
2023-12-31
First posted
2019-07-11
Last updated
2024-05-09

Locations

8 sites across 7 countries: Argentina, Chile, Mexico, Netherlands, Paraguay, Portugal, Spain

Source: ClinicalTrials.gov record NCT04015466. Inclusion in this directory is not an endorsement.